| Title |
Advances in Pharmacotherapy of Late-Life Depression
|
|---|---|
| Published in |
Current Psychiatry Reports, April 2018
|
| DOI | 10.1007/s11920-018-0899-6 |
| Pubmed ID | |
| Authors |
John L. Beyer, Kim G. Johnson |
| Abstract |
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures. Among newer antidepressants, vortioxetine has demonstrated efficacy in LLD, quetiapine has demonstrated efficacy especially for patients with sleep disturbances, and aripiprazole augmentation for treatment resistance in LLD was found to be safe and effective. Researchers have also been identifying moderators of LLD that can guide treatment. Researchers are learning how to associate moderators, neuroanatomical models, and antidepressant response. SSRI/SNRIs remain first-line treatment for LLD. Aripiprazole is an effective and safe augmentation for treatment resistance. Studies are identifying actionable moderators that can increase treatment response. |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 84 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 11% |
| Other | 6 | 7% |
| Student > Postgraduate | 6 | 7% |
| Student > Ph. D. Student | 5 | 6% |
| Researcher | 5 | 6% |
| Other | 17 | 20% |
| Unknown | 36 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 26% |
| Psychology | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Neuroscience | 3 | 4% |
| Other | 7 | 8% |
| Unknown | 39 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2023.
All research outputs
#4,160,723
of 24,452,844 outputs
Outputs from Current Psychiatry Reports
#433
of 1,244 outputs
Outputs of similar age
#77,794
of 333,214 outputs
Outputs of similar age from Current Psychiatry Reports
#15
of 31 outputs
Altmetric has tracked 24,452,844 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,244 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.1. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,214 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.